Monitoring the impact of Nirsevimab in Chile
El propósito de NirseCL es monitorear el impacto que tiene en la prevención de infecciones respiratorias por Virus Respiratorio Sincicial (VRS) en niños la inclusión de nirsevimab a la campaña de invierno en 2025 en Chile.
About the project
The NirseCL study is a collaborative effort between the Ministry of Health of Chile, the Institute of Engineering Systems Complexity (ISCI), and the Faculty of Medicine of the University of Chile. The institutions are working on obtaining and analyzing the necessary data to support the implementation of universal prophylaxis against RSV in infants and to monitor the impact of the recent inclusion of nirsevimab as part of the immunization program during the winter campaign in 2024, funded by the government.
Actualizado al 29-04-2025
*Data from hospitals that have not reported or have partially reported hospitalizations have been removed from the analysis.
Regions of Northern Macrozone: Arica y Parinacota, Tarapacá, Antofagasta, Atacama.
Regions of Central Macrozone: Coquimbo, Valparaíso, Metropolitana, O'higgins, Maule, Ñuble, BíoBío.
Regions of Southern Macrozone: Araucanía, Los Ríos, Los Lagos, Aysén, Magallanes.
Regions of Northern Macrozone: Arica y Parinacota, Tarapacá, Antofagasta, Atacama.
Regiones Macrozona Centro: Coquimbo, Valparaíso, Metropolitana, O'Higgins, Maule, Ñuble, Biobío.
Regions of Southern Macrozone: Araucanía, Los Ríos, Los Lagos, Aysén, Magallanes.
*These charts exclude information on children born outside of Chile and children with mothers of unknown nationality.